Serum IL-33 levels are increased in patients with psoriasis

Clinical and Experimental Dermatology

Volumn 41, Issue 2, 2016, Pages 183-189

  Mitsui, A ^a   Tada, Yayoi ^a   Takahashi, T ^a   Shibata, S ^a   Kamata, M ^a   Miyagaki, T ^a   Fujita, H ^a   Sugaya, M ^a   Kadono, T ^a   Sato, S ^a   Asano, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 33; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN; CYTOKINE; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KERATINOCYTE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; SKIN DISEASE; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; METABOLISM;

ADULT; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-33; INTERLEUKINS; KERATINOCYTES; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84960209342     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12670     Document Type: Article

References (25)

1. Lowes MA, Russell CB, Martin DA, et al,. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013; 34: 174-81.
2. Becher B, Pantelyushin S,. Hiding under the skin: interleukin-17-producing gammadelta T cells go under the skin? Nat Med 2012; 18: 1748-50.
3. Chen GY, Nunez G,. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-37.
4. Oboki K, Ohno T, Kajiwara N, et al,. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010; 59: 143-60.
5. Kakkar R, Hei H, Dobner S, et al,. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287: 6941-8.
6. Mirchandani AS, Salmond RJ, Liew FY,. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012; 33: 389-96.
7. Xu D, Jiang HR, Kewin P, et al,. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008; 105: 10913-18.
8. Theoharides TC, Zhang B, Kempuraj D, et al,. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 2010; 107: 4448-53.
9. Matsuyama Y, Okazaki H, Tamemoto H, et al,. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37: 18-25.
10. Pastorelli L, Garg RR, Hoang SB, et al,. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010; 107: 8017-22.
11. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
12. Hau CS, Tada Y, Shibata S, et al,. High calcium, ATP, and poly(I: C) augment the immune response to beta-glucan in normal human epidermal keratinocytes. J Invest Dermatol 2011; 131: 2255-62.
13. Ho LH, Ohno T, Oboki K, et al,. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007; 82: 1481-90.
14. Moulin D, Donze O, Talabot-Ayer D, et al,. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007; 40: 216-25.
15. Balato A, Lembo S, Mattii M, et al,. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 2012; 21: 892-4.
16. Meephansan J, Tsuda H, Komine M, et al,. Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 2012; 132: 2593-600.
17. Hueber AJ, Alves-Filho JC, Asquith DL, et al,. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011; 41: 2229-37.
18. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
19. Meephansan J, Komine M, Tsuda H, et al,. Expression of IL-33 in the epidermis: the mechanism of induction by IL-17. J Dermatol Sci 2013; 71: 107-14.
20. Schmitz J, Owyang A, Oldham E, et al,. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
21. Tamagawa-Mineoka R, Okuzawa Y, Masuda K, et al,. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol 2014; 70: 882-8.
22. Talabot-Ayer D, McKee T, Gindre P, et al,. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012; 79: 32-7.
23. Palmer G, Talabot-Ayer D, Lamacchia C, et al,. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009; 60: 738-49.
24. Partsch G, Steiner G, Leeb BF, et al,. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23.
25. Verri WA Jr, Souto FO, Vieira SM, et al,. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010; 69: 1697-703.